Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385735 | 1.00 | TLR7 (0.57) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL22158722 | 0.93 | TLR7 (0.49) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL5452417 | 0.90 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL26309527 | 0.88 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL22158688 | 0.88 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL22158715 | 0.86 | TLR7 (0.42) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL22559017 | 0.86 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL4160150 | 0.85 | TLR7 (0.49) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL6098569 | 0.85 | TLR8 (0.42) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL1486723 | 0.85 | TLR7 (0.48) | TLR7TLR8NUDT1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032478-A1 | SOLID FORMS OF RESIQUIMOD AND FORMULATIONS THEREOF | SURGE Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| US-20230355750-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | Progeneer Inc. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230346924-A1 | MRNA VACCINE COMPRISING ADJUVANT CAPABLE OF KINETIC CONTROL | Progeneer Inc. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230277525-A1 | CONJUGATE OF FUNCTIONAL DRUG AND TOLL-LIKE RECEPTOR 7 OR 8 AGONIST OF WHICH ACTIVE SITE IS TEMPORARILY INACTIVATED AND USE THEREOF | Progeneer Inc. (KR) | 2023-09-07 | — | — | US | disclosed |
| CN-116322751-A | mRNA vaccine comprising an adjuvant capable of kinetic control | 蛋白科技先锋 | 2023-06-23 | — | — | CN | disclosed |
| EP-4194010-A1 | CONJUGATE OF FUNCTIONAL DRUG AND TOLL-LIKE RECEPTOR 7 OR 8 AGONIST OF WHICH ACTIVE SITE IS TEMPORARILY INACTIVATED AND USE THEREOF | PROGENEER INC. (KR) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194008-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | PROGENEER INC. (KR) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194006-A1 | MRNA VACCINE COMPRISING ADJUVANT CAPABLE OF KINETIC CONTROL | PROGENEER INC. (KR) | 2023-06-14 | — | — | EP | disclosed |
| CN-116056725-A | Conjugate of a functional drug with temporarily inactivated active site and Toll-like receptor 7 or 8 agonist and use thereof | 蛋白科技先鋒 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022031011-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | 성균관대학교산학협력단 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022031057-A1 | CONJUGATE OF FUNCTIONAL DRUG AND TOLL-LIKE RECEPTOR 7 OR 8 AGONIST OF WHICH ACTIVE SITE IS TEMPORARILY INACTIVATED AND USE THEREOF | 성균관대학교산학협력단 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022031021-A1 | MRNA VACCINE COMPRISING ADJUVANT CAPABLE OF KINETIC CONTROL | 성균관대학교산학협력단 | 2022-02-10 | — | — | WO | disclosed |
| US-20090240055-A1 | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof | KREPSKI LARRY R | 2009-09-24 | — | — | US | disclosed |
| EP-1937683-A1 | METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007035935-A1 | METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346924-A1 | MRNA VACCINE COMPRISING ADJUVANT CAPABLE OF KINETIC CONTROL | CD69, RNGTT, RNMT | TLR7 13/4885TLR8 167/4885NUDT1 832/4885 |
| US-20090240055-A1 | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof | CYP4B1, CYP4F8, CYP4X1 | TLR7 1625/4885TLR8 3054/4885NUDT1 409/4885 |
| US-20230277525-A1 | CONJUGATE OF FUNCTIONAL DRUG AND TOLL-LIKE RECEPTOR 7 OR 8 AGONIST OF WHICH ACTIVE SITE IS TEMPORARILY INACTIVATED AND USE THEREOF | TLR8, TLR3, TLR7 | TLR7 3/4885TLR8 1/4885NUDT1 3721/4885 |
| US-20230355750-A1 | KINETICALLY ACTING ADJUVANT ENSEMBLE | GPX1, GSS, IFNG | TLR7 377/4885TLR8 407/4885NUDT1 2080/4885 |
| US-20250032478-A1 | SOLID FORMS OF RESIQUIMOD AND FORMULATIONS THEREOF | MYD88, IFNG, TLR9 | TLR7 5/4885TLR8 8/4885NUDT1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.